COMMUNIQUÉS West-GlobeNewswire

Chemed Corporation Declares Quarterly Dividend of 60 Cents
07/11/2025
CINCINNATI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company’s capital stock, [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/11/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 nov. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
07/11/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
07/11/2025
COPENHAGEN, Denmark, November 7, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% [...]
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines
07/11/2025
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines Nantes, le 7 novembre 2025, 18 heures - OSE [...]
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
07/11/2025
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines NANTES, France, November 7, 2025 – 6:00pm CET - OSE [...]
Ipsen - Octobre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/11/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/11/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
IBA – Information Réglementée
07/11/2025
7 novembre 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un [...]
IBA – Regulated information
07/11/2025
November 7 th , 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various [...]
Fagron’s share buy-back program: Weekly update
07/11/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased [...]
Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement
07/11/2025
Experience sharper focus, stronger memory, and peak cognitive performance with Neurocept—an advanced brain support supplement backed by science. New York City, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Introduction New York [...]
PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET
07/11/2025
MINNEAPOLIS, MN, US, Nov. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and its wholly-owned subsidiary Petvivo Animal Health, Inc., a leading biomedical company delivering innovative [...]
Celldex to Present at Upcoming Investor Conferences
07/11/2025
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2 nd Annual Healthcare [...]
Treace Announces Participation in Two Upcoming Investor Conferences
07/11/2025
PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
07/11/2025
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10 th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN [...]
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
07/11/2025
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and [...]
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07/11/2025
ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer [...]
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
07/11/2025
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults [...]

Pages